Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Glioblastoma is the most common and aggressive malignant brain tumor in adults. In this study, we tried to develop a new therapy that targets the interaction of glioblastoma stem cells with their specific microenvironments. We found a crucial role of the R-spondin-LGR5-APC axis in the control of Wnt signaling in glioblastoma stem cells. Moreover, R-spondin/Wnt stimuli activate Wnt signaling via promoting the phosphorylation of Axin1 at T160. Thus, small molecules that inhibit Axin1 T160 phosphorylation hold promise as novel anti-tumor reagents.
|